AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02797431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: IM administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR>2.5 or platelet count \< 35,000
Study NCT02797431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM administration of Placebo (SC administration for patients with INR>2.5 or platelet count \< 35,000
Study NCT02797431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM administration of Placebo (SC administration for patients with INR>2.5 or platelet count \< 35,000
Study NCT04428268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine Phosphate Tablets
Description: Orally administered
Study NCT04428268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Phosphate Tablets
Description: Orally administered
Study NCT01315210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Ribose Powder
Description: 5 g TID for 12 Weeks
Study NCT01315210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: 5 g TID for 12 Weeks
Study NCT02734576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous Sinus Stenting with the Precise Pro Stent
Description: Enrolled patients will undergo a minimally invasive procedure that involves placement of a stent in the cerebral venous sinuses (large veins of the brain).
Study NCT02414061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein (Arla Foods Ingredients Group)
Description: 20 g whey protein isolate added to breakfast meal
Study NCT02414061 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Breakfast meal
Description: Carbohydrate breakfast served as a standard portion (1799 kJ, 93/2/9% energy from carbohydrate/fat/protein)
Study NCT02414061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast meal
Description: Carbohydrate breakfast served as a standard portion (1799 kJ, 93/2/9% energy from carbohydrate/fat/protein)
Study NCT03028441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03028441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-CHKVLP059-00-VP
Description: Measles-vectored Chikungunya vaccine
Study NCT00769561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback-Based Cognitive Behavioral Treatment
Description: The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits.
Study NCT00769561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental treatment with occlusal splint (OS)
Description: Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment.
Study NCT02745470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Description: Colorless, transparent liquid contained in a glass prefilled syringe pen-like injection (GLP-1 receptor agonist)
Study NCT02745470 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline injection before performing fMRI
Study NCT00921024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-101
Description: intravenous
Study NCT04005573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3
Description: VD3 50000 IU/ week for 8 weeks
Study NCT04005573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega 3- FA
Description: Omega 3 FA group 300 mg once daily for 8 weeks
Study NCT04005573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3 and omega- 3FA
Description: 50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
Study NCT04005573 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: no intervention is given
Study NCT02207569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreValve Evolut R TAVR system
Study NCT01833845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: weight-based doses (1000 mg/day administered BID \[twice daily\] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects > 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.
Study NCT01833845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: subjects will receive HCQ 575 mg administered as a single tablet once daily (QD)
Study NCT02935985 — intervention group
Intervention type: OTHER
Intervention: Point-of-care bio-markers (cTnI, hsCRP, D-Dimer) and biological parameters (CBC, glucose, cholesterol, LDL cholesterol, triglycerides, fibrinogen)
Description: Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days.
Study NCT00921024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: intravenous
Study NCT02735564 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bariatric Surgery
Study NCT02735564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Study NCT02405403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714 PET
Description: \[18F\]DPA-714 Positron Emission Tomography
Study NCT01493427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Description: Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
Study NCT02225210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Loading dose:0.4μg.kg-1 Maintenance dose :0.2\~0.7µg.kg-1 Sedation-Agitation Scale: maintain between 3 and 4.
Study NCT02225210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Loading dose of midazolam:0.1mg.kg-1 . Maintenance dose of midazolam :0.05\~0.1mg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
Study NCT02225210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5\~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
Study NCT02503033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: Oral administration, once daily
Study NCT02965651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECA System
Description: The ECA system, named Gabby, included content pertaining to stress management, nutrition and physical activity as well as dialogue scripts and media such as meditations. The scripts included motivational interviewing dialogue: dialogue to simulate shared decision making interactions and additional longitudinal interaction using techniques such as goal setting, problem solving, tips, and homework. Gabby was available on a web browser through a username and secure password login.
Study NCT04559113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Injectable Product
Description: 1. 0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~2. Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day.
Study NCT02323074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Computer Interface
Study NCT04245228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Coach
Description: Trained in motivational interviewing who will call the patient weekly for 12 sessions for an approximately 30-minute intervention
Study NCT02428764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8
Study NCT02428764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.
Study NCT02428764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.
Study NCT02428764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients' resectability was assessed by a medical team, including thoracic surgeons, medical oncologists, and radiologists.
Study NCT04316351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab + Pemetrexed + Anlotinib
Description: Toripalimab 240 mg iv d1 + anlotinib 12mg po d1-d14 + pemetrexed 500mg / m2 d1 Q3W for 4 cycles, followed by Toripalimab 240mg iv d1 + anlotinib 12mg po d1 + pemetrexed 500mg / m2 d1 Q3W for another 31 cycles (up to a total of 35 cycles).~If there is no disease progression, patients will receive anlotinib po 12mg d1-d14 + pemetrexed 500mg / m2 d1, Q3W for maintenance therapy until PD per RECIST v1.1 or loss of clinical benefit.
Study NCT02323074 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Brain Computer Interface
Study NCT03052205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2125
Description: IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
Study NCT01981252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT02334423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin, Type A
Description: Botulinum toxin, Type A
Study NCT02334423 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sterile, unpreserved saline
Description: Placebo
Study NCT01635777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: 2.5 mg/kg/day for 12 weeks
Study NCT01635777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: 2.5 mg/kg/day for 8 weeks
Study NCT03758859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate eyedrops
Description: sodium hyaluronate eyedrops administered - route ocular -topical
Study NCT03214640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rivanna Accuro US Device
Description: When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Rivanna Accuro U/S device. For subjects in group C-R or L-R, the needle insertion site will be the site identified by the Rivanna Accuro U/S device. After placement of spinal for Cesarean or epidural for labor, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
Study NCT03214640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palpation
Description: When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Palpation method using conventional landmarks (spinous process and iliac crest). For subjects in group C-P or L-P, the needle insertion site will be the site identified by the Palpation method. After placement of spinal for Cesarean or epidural for labor, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
Study NCT03214640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuraxial Analgesia
Description: Labor analgesia will be provided utilizing the standard medications to provide labor analgesia
Study NCT03214640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuraxial Analgesia
Description: Labor analgesia will be provided utilizing the standard medications to provide labor analgesia
Study NCT03214640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Block
Description: Spinal anesthetic medications will be utilized in providing surgical block for cesarean delivery as is standard of care
Study NCT03214640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Block
Description: Spinal anesthetic medications will be utilized in providing surgical block for cesarean delivery as is standard of care
Study NCT01035359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External fixation
Description: Bridging external fixation of a distal radius fracture with an optional addition of k-wire(s)
Study NCT02860052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB208 2%
Description: Apply once daily to one or both feet for 14 days
Study NCT01035359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volar plate
Description: Operation of distal radius fracture with open reduction and fixation with a plate from the volar side of the wrist.
Study NCT02988362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL068 16/10mg
Description: Candesartan 16mg and Amlodipine 10mg
Study NCT02988362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 16mg and Amlodipine 10mg
Study NCT02860052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB208 4%
Description: Apply once daily to one or both feet for 14 days
Study NCT02860052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB208 16%
Description: Apply once daily to one or both feet for 14 days
Study NCT02860052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Apply once daily to one or both feet for 14 days
Study NCT04239924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paramedic Coaching
Description: The intervention is an adaptation of the evidence-based REACH program, specific coaching content is delivered by paramedics in 1-2 hour in-home sessions and over the phone throughout a 12-month period.
Study NCT02926898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 (Fenfluramine Hydrochloride)
Description: ZX008 0.5 mg/kg/day (maximum 20 mg/day). ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL.~\*Note: The 0.5 mg/kg/day dose of ZX008 fenfluramine hydrochloride in this study is equivalent to 0.4 mg/kg/day (maximum 17 mg/day) dose of fenfluramine base.
Study NCT02926898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo
Study NCT02396329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Study NCT03069989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008348
Description: Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
Study NCT02396329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Study NCT03827083 — intervention group
Intervention type: OTHER
Intervention: cerebral pulse oximetry
Description: Cognitive Functions by Cerebral Pulse Oximetry After General Anesthesia and Spinal Anesthesia
Study NCT03069989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.
Study NCT03069989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FBA-A20FMDV2
Description: Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
Study NCT03069989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [18F]-FBA-A20FMDV2
Description: Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
Study NCT03184246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: videolaryngoscopy (GlideScope) will be used for intubation
Study NCT03184246 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: direct laryngoscopy will be used for intubation
Study NCT05047744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Touch Dual Mobility CMC I Prosthesis
Description: Surgery
Study NCT00067340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse
Description: women received daily chlorhexidine oral rinses for two weeks prior to delivery of the infant.
Study NCT00067340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Description: Women were asked to chew xylitol chewing gum three times per day following the birth of their infant for up to two years postpartum
Study NCT03710954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: All volunteers were evaluated by numerical pain scale and Fuzzy scale. This procedure was performed to compare the efficacy of the Fuzzy Scale demonstrating greater accuracy of quantification of skeletal muscle pain
Study NCT00276302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: IV administration of IPI-504 for 21-day cycles. Two different schedules of treatment will be tested. On Schedule A, doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration. On Schedule B, doses occur on Days 1, 4, 8, 11, 15, and 18, or twice weekly for 3 weeks continuously.~For both Schedule A and B doses will be administered ≥ 72 hours apart.
Study NCT00982345 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: quetiapine (Seroquel XR)
Description: Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.
Study NCT04321889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: defurocumarinized bergamot loaded in a nanotechnological essential oil release system
Description: Patients will be treated either with placebo cream or with defurocumarinized bergamot loaded in a nanotechnological system of essential oil release in the pharmaceutical form of cream 2 times a day for 4 weeks. The subject will be monitored throughout the treatment and for at least 4 weeks after the end of the treatment.
Study NCT04321889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nanotechnological system loaded with placebo cream
Study NCT02855255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NHS 1-1 smoking cessation programme.
Description: Smoking cessation using cognitive behavioural therapy/motivational interviewing
Study NCT02855255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group smoking cessation programme
Description: Smoking cessation using Allen Carr's Easyway method being delivered in a spoken form.
Study NCT01100788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short chain fructo-oligosaccharide (scFOS) 5 g
Description: Dietary Supplement: scFOS 5 g~Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew.
Study NCT01100788 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment without scFOS fiber
Study NCT01100788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short chain fructooligosaccharide (scFOS) 8 g
Description: Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.
Study NCT01673386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Study NCT01673386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Study NCT00812253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous insulin
Description: Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
Study NCT00812253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous insulin
Description: Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.